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Abstract
Objective—In Vietnam, where 58% of prevalent HIV cases are attributed to PWID, we evaluated 
whether a multi-level intervention could improve care outcomes and increase survival.
Methods—We enrolled 455 HIV-infected male PWID from 32 communes in Thai Nguyen 
Province. Communes were randomized to a community stigma reduction intervention or standard 
of care and then within each commune, to an individual enhanced counseling intervention or 
standard of care, resulting in four arms: Arm 1 (standard of care); Arm 2 (community intervention 
alone); Arm 3 (individual intervention alone); and Arm 4 (community + individual interventions). 
Follow-up was conducted at 6, 12, 18, and 24 months to assess survival.
Results—Overall mortality was 23% (n = 103/455) over two years. There were no losses to 
follow-up for the mortality endpoint. Survival at 24-months was different across arms: Arm 4 
(87%) vs Arm 1 (82%) vs Arm 2 (68%) vs Arm 3 (73%); log-rank test for comparison among 
arms: p=0.001. Among those with CD4 cell count <200 cells/mm3 and not on antiretroviral 
therapy (ART) at baseline (n=162), survival at 24 months was higher in Arm 4 (84%) compared to 
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other arms (Arm 1: 61%; Arm 2: 50%; Arm 3: 53%; p-value=0.002). Overall, Arm 4 (community 
+ individual interventions), increased uptake of ART compared to Arms 1, 2, and 3.
Conclusion—This multi-level behavioral intervention appeared to increase survival of HIV-
infected participants over a two-year period. Relative to the standard of care, the greatest 
intervention effect was among those with lower CD4 cell counts.
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Introduction
People who inject drugs (PWID) are at increased risk of mortality compared to their non-
injecting peers, primarily due to blood borne infections and drug overdose.1,2 For HIV-
infected PWID, crude mortality rates are 3 times higher than for HIV-uninfected PWID, 
underscoring the impact of delayed diagnosis and entry into antiretroviral therapy.3 HIV-
infected PWID are less likely to be engaged in the HIV care continuum4 than other key 
populations. Globally, only 36% of PWID have received an HIV test and know their result,4 
and approximately 4% of HIV-infected PWID receive antiretroviral therapy (ART).5 PWID 
initiate care at a later state of infection6,7 and experience poorer outcomes when ART 
initiation is delayed.8,9
In Vietnam, the HIV epidemic is concentrated primarily among PWID, who currently 
account for an estimated 58% of reported infections.10 As in many countries, injecting drug 
use is both criminalized and stigmatized in Vietnam. PWID encounter discrimination in 
health care settings11 and HIV stigma and social isolation present considerable barriers to 
access to care and support for HIV.12,13 We hypothesized that a multi-level intervention that 
combined an individual level component that provides support, risk-reduction skills, and 
resilience to stigma with a community-level component that aimed to reduce HIV and 
PWID-related stigma in the community would improve access to ART and reduce mortality 
compared to each component alone or the standard of care.
Methods
The study was approved by the ethical review committees at the Johns Hopkins Bloomberg 
School of Public Health and the Thai Nguyen Center for Preventive Medicine.
The study was conducted in Thai Nguyen, a mountainous province in northeast Vietnam 
located 50 miles from the capital, Hanoi. Thai Nguyen is close to the China border and has a 
tradition of opium cultivation and use. In 2009, at the start of this study, there were an 
estimated 6418 PWID14 in the province and a total of 7 outpatient antiretroviral treatment 
clinics and no MMT clinics. At the time of the study, ART eligibility criteria were having a 
CD4 cell count <200 cells/mm3 with HIV stage 1 and 2. PWID face severe social 
marginalization within families and communities,15,16 and they may be subject to 
compulsory detoxification and incarceration and are discriminated against in health care 
settings.11 As a result, they are difficult to reach for intervention and care and treatment 
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programs17 and are underrepresented in ART clinics. The province consists of 180 
communes and the average population in each commune is approximately 10,000.
Study design
Our multi-level intervention was evaluated using a four-arm randomized controlled trial: 
Arm 1: a standard of care condition; Arm 2: community-level stigma reduction programs; 
Arm 3: individual-level HIV post-test counseling and skill-building support groups; and 
Arm 4: both community and individual level activities. Details of the trial and our primary 
outcomes are reported elsewhere.18
Randomization
The study design was as follows: first, out of the 180 communes in Thai Nguyen, the 32 
communes with the largest number of people who inject drugs were selected. The 32 
communes were then partitioned into 9 groups (2 groups with 2 communes each, and 7 
groups with 4 communes each) (Table 1), so that within each group the communes were 
similar in number of drug users and population. Within each group, a random half of the 
communes were selected to receive the community level stigma reduction and the remaining 
communes were selected to receive the standard of care. Within each commune, regardless 
of stigma reduction assignment, a random half of index participants were assigned to receive 
enhanced post-test HIV counseling and skill building and the other half received the 
standard of care.
Participants
From July 2009–January 2011, index participants were recruited by a team of seven 
recruiters who themselves were former or current drug users. Using a snowball sampling 
technique, recruiters approached their current or former drug networks in a private place and 
distributed brochures and answered questions about the study. They then accompanied or 
referred subjects who were interested in participating to the project office to be screened for 
eligibility. Because almost all (97%) of PWID in Thai Nguyen are male (and female PWID 
typically have different risk factors19,20), our study focused on male drug injectors. To be 
eligible for our study, individuals had to have an HIV-positive diagnosis confirmed through 
testing by our study, be able and willing to bring in an injecting network member for 
screening, be male, be 18 years of age or older, have had sex in the previous six months, 
have injected drugs in the previous six months and have planned to be a resident in Thai 
Nguyen for the next 24 months. Individuals who were unwilling to provide locator 
information or were currently participating in other HIV interventions were excluded from 
the trial. Subsequently, recruited network partners were not included in this analysis as they 
were HIV-uninfected (as per study design).
Procedures
Participants received HIV testing and counseling and a face-to-face interview using a 
structured questionnaire at the screening visit. Two rapid HIV antibody tests were run 
simultaneously (Determine: Abbot Laboratories, Abbott Park, IL and Bioline: SD, Toronto 
Canada)21 and discordant results were resolved through a third rapid assay (HIV Rapid Test: 
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ACON, San Diego, CA). Results were provided at the screening visit, but we enrolled 
participants at a later visit so that individuals would have the opportunity to process the 
results of their tests.
Index participants were asked to provide blood specimens at the 6, 12, 18 and 24 months 
follow-up visits in order to assess the stage of their HIV disease. Follow-up interviews, 
approximately an hour in length, were administered face-to-face in a private room at the 
project office by trained interviewers. Participants were reimbursed 75,000 Vietnamese 
Dong, equivalent to $3.50 USD, at each visit and 5000 Vietnamese Dong ($0.23 USD) for 
each kilometer traveled.
The intervention is described in detail elsewhere.18 Briefly, men randomized to the 
individual level standard of care arm received pre-test and post-test HIV and sexually 
transmitted diseases counseling and appropriate referrals. Men randomized to the individual 
level intervention arm received the following services: 1) two additional individual HIV 
posttest counseling sessions that included discussion about coping with stigma, social 
support, partner testing, and disclosure; 2) two small group sessions with other participants 
that focused on HIV knowledge, injecting and sexual risk reduction, and skill-building for 
coping with HIV infection and also provided social support through shared experiences of 
being an HIV-infected PWID. Participants were also offered an optional “person important 
to me” (PIM) session which focused on how the PIM could best support the participant in 
coping with HIV and reducing HIV risk behaviors. The individual level intervention was 
delivered over 5 weeks and builds on an overall staged sequential approach to behavior 
change for HIV-infected PWID.
Communes randomized to the standard of care arm received standard messages on HIV 
through village weekly public loudspeakers and educational pamphlets that were already 
being provided by community health stations.
Communes randomized to the intervention arm received community-wide programs that 
aimed to reduce community HIV and injection drug-related stigma by correcting 
misconceptions about HIV transmission, de-linking people living with HIV from “social 
evils” and promoting positive messages on HIV and drug use in the community. Specifically, 
two 2-session video-screenings were held in the intervention communes. These videos were 
developed by our team in collaboration with Johns Hopkins University’s Center for 
Communication Programs and were based on formative research conducted prior to the trial. 
The video was piloted with focus groups of community members in the province prior to 
use. Each video presentation was followed by a question-answer session on HIV with a 
trained facilitator. On average, approximately 44 community members attended the video 
screening. The program was supplemented by community outreach that took place 
throughout the study period. Three teams of community mobilization volunteers 
disseminated HIV information and answered questions through six rounds of a combination 
of one-on-one and group discussions in the community.18
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Outcomes
During baseline and all follow-up visits index participants completed a face-to-face survey 
with an interviewer in a private room at the study office. Surveys collected information on 
age, education, marital status, employment status, sexual risk behaviors, injecting behaviors, 
and HIV and injection drug use-related stigma.
Additionally at each follow-up visit, each index participant was asked to provide blood 
specimens to assess CD4 cell count, and received a follow-up physical examination by the 
study physician.
Antiretroviral treatment—At each visit, participants were asked if they used ART in the 
six months prior to the interview. After the interview, they received a follow-up physical 
examination by the study physician where the physician asked about ART use in prior six 
months. A kappa statistic was calculated and indicated strong agreement (85.5%) between 
the two reports of ART status. For analyses, we used the physician-reported ART status; if 
physician-reported ART status was missing then self-reported ART status was used.
Mortality—All participants who missed a follow-up visit were contacted through study 
outreach workers, using contact information collected at baseline. During tracing 
procedures, family members of participants informed the study team if a participant died. 
We conducted a verbal autopsy during which we established date and reported cause of 
death. For analysis, “time of death” is the first scheduled follow-up visit after death.
Statistical analysis
Mortality and hazard of death rates were estimated by the Kaplan-Meier estimator and 
Nelson-Aalen estimator for each arm separately. Hazard rates across arms were compared 
using the log-rank statistic, whose significance level was obtained from its exact distribution 
over the permutation of the matched-cluster treatment assignment process22 as defined by 
the design above.
Mortality information was complete for all participants regardless of completion of visits, 
and so mortality analysis required no adjustment. Baseline antiretroviral treatment and CD4 
cell count data were provided for 443 (97%) participants. For the analysis of hazard of death 
for participants who were not on ART throughout the study, at least one of the antiretroviral 
reports was not available for 194 participants. Antiretroviral treatment, whenever observed, 
was monotone across visits (either no use throughout, or complete uses, or initiating 
treatment) for 97% of participants. Missing treatment data were addressed with the 
technique of multiple imputation,23 which has recently been considered by a National 
Academy of Sciences report as among the best for treating missing data.24
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
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Results
Table 2 describes baseline demographics and injecting and sex behaviors by arm. The mean 
age of all participants was 35.2 years, 47% were married and 70% were working full time. 
There were no significant differences between arms with respect to any demographic or risk 
characteristics.
The overall mortality was 23% (n = 103/455) over a two-year period. Causes of mortality 
were HIV-related [TB, bacterial infections, malignant neoplasm, unspecified malignancy, 
wasting syndromes, or other infections stemming from HIV] (72%), drug overdose (11%), 
suicide (5%), and injury (3%). There was no loss to follow-up for the mortality endpoint. 
There is a statistically significant difference between Arm 1 (standard of care) versus Arm 2 
(community alone) versus Arm 3 (individual alone) versus Arm 4 (community + individual) 
(p = 0.001) (Figure 1; Table 3a).
In order to understand the factors driving this difference, we looked at mortality across arms 
within three strata: those on ART at baseline, those eligible for ART (CD4 cell count <200 
cells/mm3) but not on ART at baseline, and those not eligible and not on ART at baseline. 
We see no difference in mortality across arms for those on ART or those not eligible and not 
on ART. However, Arm 4 (community + individual) has statistically significantly lower 
mortality than Arm 1 (standard of care) for those eligible but not on ART at baseline 
(p=0.008) (Table 3b). In summary, for participants who are eligible but not on ART at 
baseline, the combined intervention (Arm 4 community + individual) increases survival 
compared to the standard of care arm.
Tables 4 and 5 investigate whether the mortality difference across arms in Tables 3a and 3b 
is accounted for by higher uptake of ART (Table 4) and/or if the mortality difference across 
arms exists also among those not taking ART (Table 5). In Table 4, the 38% transition 
probability tabulated for Arm 1 (standard of care) at 6 months is the fraction of individuals 
who start ART at 6 months among those who were alive at that visit and had not been taking 
ART up to the 6 month visit, among individuals who have CD4 cell count <200 cells/mm3 at 
baseline. Transition probabilities were not statistically significantly different based on a 
comparison of all four arms (p=0.158), although Arm 4 (community + individual) was 
statistically significantly different in comparison to the other three arms (p=0.033).
In Table 5, the percent tabulated at each visit (e.g., 24% for Arm 3 at 18 months) among 
those not on ART prior to that visit and with baseline CD4 cell count <200 cells/mm3, is the 
fraction of the individuals who died since the prior (12 month) visit among all individuals in 
the stratum who were alive and not on treatment at the previous visit. Hazard rates of death 
accumulating information across all visits are lower for Arm 4 (community + individual) 
compared to the other arms (p=0.001 for comparison among all arms) for individuals who 
were not on ART.
Discussion
Despite the high mortality rates of HIV-infected PWID, few interventions have focused on 
improving health outcomes in this population,25,26 and to our knowledge, this is the first 
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study to look at the effect of a multi-level intervention on preventing mortality among HIV-
infected PWID. The multi-level behavioral intervention appeared to increase survival over a 
two-year period. Relative to the standard of care, the greatest intervention effect was among 
those with lower CD4 cell counts, where starting antiretroviral treatment is most 
advantageous.
Specifically, Table 3a shows an overall effect of the interventions on mortality for all index 
participants comparing all 4 arms (Arm 1 versus Arm 2 versus Arm 3 versus Arm 4). We 
then conducted further analysis to understand the differences between arms. We found that 
among those who had baseline CD4 cell count ≥200 cells/mm3 (and therefore did not meet 
eligibility criteria for ART at the time), there was not a statistically significant difference in 
mortality between arms (logrank = 7.1, 3 df, p-value = 0.077, data not shown). Furthermore, 
among those who had a CD4 cell count <200 cells/mm3 and were on ART at baseline, there 
were no statistically significant differences in mortality between arms (logrank = 0.11, 3 df, 
p-value = 0.99, data not shown).
Among those with a CD4 cell count below 200 cells/mm3 and who were not on ART at 
baseline, the higher mortality in Arm 2 (community alone) and Arm 3 (individual alone) is 
not significant compared to Arm 1 (standard of care), whereas the difference between Arm 1 
(standard of care) and Arm 4 (community + individual) is statistically significant. Although 
not statistically significant, Arms 2 and 3 did have a higher mortality than the standard of 
care arm. This may be because individuals in Arm 2 (community alone) and Arm 3 
(individual alone) perceived they were receiving care and/or support, but did not have either 
sufficient skills and/or community support to obtain and maintain HIV medical care. The 
perception that they received valuable services from the intervention may have made them 
less motivated to seek medical care.
Globally, drug users have poor engagement in every step of the HIV care continuum. In our 
study, those in the community + individual arm (Arm 4) were more likely to initiate ART, 
and subsequent to ART initiation there was no difference in mortality among arms. This 
finding is similar to other studies that show that initiation of ART is associated with survival 
both among HIV-infected PWID and people who live with HIV more generally.27–30 Uptake 
of ART in the combined community + individual intervention group occurred more rapidly 
with increased probability of initiating ART within the initial six months. In addition, the 
results in Table 5 suggest that the combined intervention lowered mortality through 
pathways other than ART for those with CD4 cell count <200 cells/mm3 at baseline. 
Specifically, among those who were ART-free prior to a particular visit, participants in the 
community + individual arm also had a significantly lower mortality rate over the 24-month 
period of observation. Similar to the uptake of HIV treatment, this difference was observed 
even in the first six months suggesting that the intervention had an almost immediate effect 
on survival. Our findings indicate that enhanced individualized counseling and small group 
support sessions should be conducted within a broader supportive community environment. 
The synergistic effect of individual and community level programs may have enhanced self-
efficacy and response efficacy for participants to navigate the HIV care system while 
simultaneously alleviating fear both of being exposed as HIV-infected and of subsequent 
stigmatization.
Go et al. Page 7
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 March 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Our intervention addressed HIV risk, coping, stigma, and social support at the individual and 
community levels among highly marginalized HIV-infected PWID who have poor physical 
health, are more likely to experience social disadvantage, and are more likely to engage in 
risky behaviors. In order to understand other possible pathways, in addition to antiretroviral 
therapy, through which mortality decreased in the community + individual arm, we 
conducted sub-analyses to assess potential mediators between intervention arm and 
mortality, including self-reported overdose, social support, symptoms of depression, visits to 
HIV providers, and physician-reported presence of opportunistic infections. None of the 
variables we assessed were statistically significant mediators, suggesting that variables 
affecting mortality excluding antiretroviral treatment uptake, may not have been adequately 
measured in our study. For example, participants in the community + individual arm may 
have had more self-efficacy or community support and been more likely to see a general 
physician for opportunistic infections. In addition, participants in the community + 
individual arm may have reduced risk-taking behaviors and thereby reduced HIV and/or 
violence/injury-related mortality.
The study was conducted in a context where study conditions could not be tightly controlled 
for self-reporting bias, attrition, secular trends, historic factors, and contamination. Our 
previous randomized controlled trial investigated the possible presence of these conditions 
and did not find evidence that they influenced results.31 However, the chance that any of 
these factors may be operating cannot be ruled out. Given the high mobility of this 
population, 44% of participants missed at least one of the four follow-up visits, which is a 
limitation to our mediation analyses. Incarceration among this population was not 
uncommon. Overall 158 participants dropped out of the study. Of those, 37 (23%) were 
incarcerated, while 103 died and 18 dropped out for other reasons. A total of 58 participants 
were incarcerated during the study period, and of those, 37 (63.7%) dropped out of the study 
due to incarceration. However, the rate of incarceration did not differ by study arm and is 
therefore is unlikely to have affected the association between the interventions and mortality. 
Overall mortality includes mortality that may not be HIV or drug related (in this study, 12%) 
and therefore might not have been in the path that can be affected by the intervention. 
Methadone Maintenance Therapy (MMT) was introduced to Thai Nguyen on March 2012. 
We do not have data on how many participants enrolled in MMT during the last year of the 
study. MMT may have reduced mortality by preventing drug overdose; however, similar to 
incarceration, we would not expect there to be a difference in enrollment into MMT by study 
arm. In addition, several potential mediators, including overdose, social support, and 
symptoms of depression, were self-reported and social desirability bias may have 
contributed to our results.
Despite these limitations, our study demonstrates that a multi-level intervention may be 
effective in increasing survival among HIV-infected PWID. The intervention was well 
attended by index participants, with 83% attending all sessions at each level. It is important 
to note that since the completion of the study, there has been a dramatic change in the 
availability of ART and MMT. ART eligibility guidelines in Vietnam changed in December 
2014, to include ART for HIV-infected individuals in mountainous regions and high risk 
groups (including PWID), regardless of CD4 cell count, and among all other HIV-infected 
persons, ART for those with CD4 cell count <500 cells/mm3. There are currently 3546 
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patients on ART in 10 ART clinics in Thai Nguyen province. In addition, the first MMT 
clinic opened in Thai Nguyen in 2011, during our study. There are currently 6 MMT clinics 
in Thai Nguyen, with 1729 patients on MMT. Increased access to ART and MMT should in 
theory, compound the effect of our intervention. In order understand the applicability of this 
intervention to other settings, this intervention may need to be evaluated in settings where 
social norms may play a less influential role on individual behaviors. This intervention is 
relatively intense, requiring two individual post-test counseling sessions, two small support 
group sessions, and a community-wide video and discussions. To assess the scalability of 
this program, it may be necessary to consider the cost-effectiveness of this intervention and 
to explore the minimum intervention dose needed to reduce mortality. Overall, our results 
suggest the importance of intervening on social and individual factors simultaneously.
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Figure 1. 
Kaplan-Meier plots of survival probability across the study follow-up for the four trial arms
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Table 4
Differences in the transition probability of initiating ART among index participants who had CD4 cell count 
<200 cells/mm3 and were not on ART at baseline, over 24 months, across trial arms
6 months
% Initiated ART
(n)
12 months
% Initiated ART
(n)
18 months
% Initiated ART
(n)
24 months
% Initiated ART
(n)
Arm 1: Standard of care 38% (10) 32% (4) 32% (2) 68% (3)
Arm 2: Community alone 50% (21) 43% (6) 9% (1) 20% (1)
Arm 3: Individual alone 33% (8) 46% (6) 20% (1) 40% (1)
Arm 4: Community + Individual 59% (25) 44% (7) 60% (6) 43% (1)
Comparison: log rank (df), p-value
Any difference between arms 5.19 (3), 0.158
Arm 4 vs. Other Arms 4.56 (1), 0.033
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Table 5
Hazard of death at each follow-up visit among index participants who had not been on ART prior to that visit 
and had CD4 cell count <200 cells/mm3 at baseline, by trial arm
6 months 12 months 18 months 24 months
Arm 1: Standard of care 19% (6) 10% (2) 21% (2) 12% (1)
Arm 2: Community alone 25% (14) 29% (6) 23% (2) 50% (3)
Arm 3: Individual alone 20% (6) 25% (4) 24% (2) 25% (1)
Arm 4: Community + Individual 7% (3) 0% (0) 0% (0) 26% (1)
Comparison: log rank (df), p-value
Any difference between arms 11.1 (3), 0.001
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 March 05.
